2 results
Approved WMOCompleted
Primary: To determine whether ofatumumab 3, 30 or 60 milligrams (mg) given subcutaneously (SQ), reduces the cumulative number of new T1 GdE brain lesions over a period of 12 weeks, as compared with placebo.Secondary: Cumulative number of new T1 GdE…
Approved WMOCompleted
In order to set up paradigms for pharmaco-MRI studies for development of novel psychotropic medications. The present study will investigate the effect of: - low-dose benzodiazepine on brain activation and test performance on a testbed of well…